These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

223 related items for PubMed ID: 20937977

  • 1. Lasofoxifene and cardiovascular events in postmenopausal women with osteoporosis: Five-year results from the Postmenopausal Evaluation and Risk Reduction with Lasofoxifene (PEARL) trial.
    Ensrud K, LaCroix A, Thompson JR, Thompson DD, Eastell R, Reid DM, Vukicevic S, Cauley J, Barrett-Connor E, Armstrong R, Welty F, Cummings S.
    Circulation; 2010 Oct 26; 122(17):1716-24. PubMed ID: 20937977
    [Abstract] [Full Text] [Related]

  • 2. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women.
    Barrett-Connor E, Mosca L, Collins P, Geiger MJ, Grady D, Kornitzer M, McNabb MA, Wenger NK, Raloxifene Use for The Heart (RUTH) Trial Investigators.
    N Engl J Med; 2006 Jul 13; 355(2):125-37. PubMed ID: 16837676
    [Abstract] [Full Text] [Related]

  • 3. Lasofoxifene in postmenopausal women with osteoporosis.
    Cummings SR, Ensrud K, Delmas PD, LaCroix AZ, Vukicevic S, Reid DM, Goldstein S, Sriram U, Lee A, Thompson J, Armstrong RA, Thompson DD, Powles T, Zanchetta J, Kendler D, Neven P, Eastell R, PEARL Study Investigators.
    N Engl J Med; 2010 Feb 25; 362(8):686-96. PubMed ID: 20181970
    [Abstract] [Full Text] [Related]

  • 4. Prevention of bone loss in postmenopausal women treated with lasofoxifene compared with raloxifene.
    McClung MR, Siris E, Cummings S, Bolognese M, Ettinger M, Moffett A, Emkey R, Day W, Somayaji V, Lee A.
    Menopause; 2006 Feb 25; 13(3):377-86. PubMed ID: 16735934
    [Abstract] [Full Text] [Related]

  • 5. Breast cancer incidence in the randomized PEARL trial of lasofoxifene in postmenopausal osteoporotic women.
    LaCroix AZ, Powles T, Osborne CK, Wolter K, Thompson JR, Thompson DD, Allred DC, Armstrong R, Cummings SR, Eastell R, Ensrud KE, Goss P, Lee A, Neven P, Reid DM, Curto M, Vukicevic S, PEARL Investigators.
    J Natl Cancer Inst; 2010 Nov 17; 102(22):1706-15. PubMed ID: 21051656
    [Abstract] [Full Text] [Related]

  • 6. A randomised, double-blinded, placebo-controlled, trial to determine the individual response in bone turnover markers to lasofoxifene therapy.
    Rogers A, Glover SJ, Eastell R.
    Bone; 2009 Dec 17; 45(6):1044-52. PubMed ID: 19665601
    [Abstract] [Full Text] [Related]

  • 7. [Lasofoxifene, a next generation estrogen receptor modulator: preclinical studies].
    Maeda T, Ke HZ, Simmons H, Thompson D.
    Clin Calcium; 2004 Oct 17; 14(10):85-93. PubMed ID: 15577137
    [Abstract] [Full Text] [Related]

  • 8. Lasofoxifene in osteoporosis and its place in therapy.
    Swan VJ, Hamilton CJ, Jamal SA.
    Adv Ther; 2010 Dec 17; 27(12):917-32. PubMed ID: 21080249
    [Abstract] [Full Text] [Related]

  • 9. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women.
    Ridker PM, Cook NR, Lee IM, Gordon D, Gaziano JM, Manson JE, Hennekens CH, Buring JE.
    N Engl J Med; 2005 Mar 31; 352(13):1293-304. PubMed ID: 15753114
    [Abstract] [Full Text] [Related]

  • 10. Treatment with alendronate prevents fractures in women at highest risk: results from the Fracture Intervention Trial.
    Ensrud KE, Black DM, Palermo L, Bauer DC, Barrett-Connor E, Quandt SA, Thompson DE, Karpf DB.
    Arch Intern Med; 2005 Mar 31; 157(22):2617-24. PubMed ID: 9531231
    [Abstract] [Full Text] [Related]

  • 11. Risk-benefit profile for raloxifene: 4-year data From the Multiple Outcomes of Raloxifene Evaluation (MORE) randomized trial.
    Barrett-Connor E, Cauley JA, Kulkarni PM, Sashegyi A, Cox DA, Geiger MJ.
    J Bone Miner Res; 2004 Aug 31; 19(8):1270-5. PubMed ID: 15231013
    [Abstract] [Full Text] [Related]

  • 12. Lasofoxifene for postmenopausal women with osteoporosis.
    Silva-Fernández L, Andreu JL.
    N Engl J Med; 2010 Jun 10; 362(23):2228; author reply 2228-9. PubMed ID: 20568310
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Estrogen plus progestin and the risk of coronary heart disease.
    Manson JE, Hsia J, Johnson KC, Rossouw JE, Assaf AR, Lasser NL, Trevisan M, Black HR, Heckbert SR, Detrano R, Strickland OL, Wong ND, Crouse JR, Stein E, Cushman M, Women's Health Initiative Investigators.
    N Engl J Med; 2003 Aug 07; 349(6):523-34. PubMed ID: 12904517
    [Abstract] [Full Text] [Related]

  • 15. Relationship between osteoporosis and cardiovascular disease in postmenopausal women.
    Tankó LB, Christiansen C, Cox DA, Geiger MJ, McNabb MA, Cummings SR.
    J Bone Miner Res; 2005 Nov 07; 20(11):1912-20. PubMed ID: 16234963
    [Abstract] [Full Text] [Related]

  • 16. Effect of pravastatin on cardiovascular events and mortality in 1516 women with coronary heart disease: results from the Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) study.
    Hague W, Forder P, Simes J, Hunt D, Tonkin A, LIPID Investigators.
    Am Heart J; 2003 Apr 07; 145(4):643-51. PubMed ID: 12679760
    [Abstract] [Full Text] [Related]

  • 17. Clinical features and outcomes of women with unstable ischemic heart disease: observations from metabolic efficiency with ranolazine for less ischemia in non-ST-elevation acute coronary syndromes-thrombolysis in myocardial infarction 36 (MERLIN-TIMI 36).
    Mega JL, Hochman JS, Scirica BM, Murphy SA, Sloan S, McCabe CH, Merlini P, Morrow DA.
    Circulation; 2010 Apr 27; 121(16):1809-17. PubMed ID: 20385930
    [Abstract] [Full Text] [Related]

  • 18. Effects of 3 years of lasofoxifene treatment on bone turnover markers in women with postmenopausal osteoporosis.
    Eastell R, Reid DM, Vukicevic S, Ensrud KE, LaCroix AZ, Thompson JR, Thompson DD, Cummings SR.
    Bone; 2012 May 27; 50(5):1135-40. PubMed ID: 22348983
    [Abstract] [Full Text] [Related]

  • 19. Another selective estrogen-receptor modulator for osteoporosis.
    Becker C.
    N Engl J Med; 2010 Feb 25; 362(8):752-4. PubMed ID: 20181977
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.